Skip Navigation

JNCI Journal of the National Cancer Institute 2004 96(16):1231-1239; doi:10.1093/jnci/djh226
© 2004 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (13)
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Drosten, M.
Right arrow Articles by Pützer, B. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Drosten, M.
Right arrow Articles by Pützer, B. M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2004 Oxford University Press

ARTICLE

Role of MEN2A-Derived RET in Maintenance and Proliferation of Medullary Thyroid Carcinoma

Matthias Drosten, Gero Hilken, Miriam Böckmann, Florian Rödicker, Nikica Mise, Aaron N. Cranston, Uta Dahmen, Bruce A. J. Ponder, Brigitte M. Pützer

Affiliations of authors: Department of Vectorology and Experimental Gene Therapy, University of Rostock, Rostock, Germany (MD, MB, FR, NM, BMP); Central Animal Facility (GH), Department of General and Transplantation Surgery (UD), University of Essen Medical School, Essen, Germany; University of Cambridge and Cancer Research UK, Department of Oncology, Cambridge, United Kingdom (ANC, BAJP)

Correspondence to: Brigitte M. Pützer, MD, PhD, Department of Vectorology and Experimental Gene Therapy, University of Rostock, Schillingalle 70, D-18055 Rostock, Germany (e-mail: brigitte.puetzer{at}med.uni-rostock.de)

Background: Dominant-activating mutations in the RET protooncogene, a receptor tyrosine kinase, have been identified as a cause of medullary thyroid carcinoma. Such oncogenic RET mutations induce its ligand-independent constitutive trans-autophosphorylation. We investigated the role of endogenous oncogenic RET autophosphorylation in maintaining the neoplastic phenotype in medullary thyroid carcinoma cells and orthotopic medullary thyroid carcinomas in RET transgenic mice. Methods: We constructed adenoviral vectors expressing a dominant-negative truncated form of RET, termed RET{Delta}TK, and analyzed its effect on cell viability, apoptosis, and proliferation of TT medullary thyroid carcinoma cells. We investigated the effect of RET{Delta}TK on downsteam signaling by assessing alterations in phosphorylation or in gene expression. The effect of RET{Delta}TK in primary medullary thyroid carcinomas in transgenic mice was assessed by monitoring tumor growth. All statistical tests were two-sided. Results: Cell viability was reduced. Phosphorylation of Akt and extracellular signal-regulated kinase (ERK), components of downstream signal transduction pathways, was abolished, and cell cycle progression was reduced. Expression of cell cycle regulator cyclin D1 was decreased, and expression of cell cyle regulators p21CIP1/WAF1 and p27KIP1 was increased. Apoptosis was stimulated and concurrently the expression of BCL-2 was decreased. All in vitro experiments compared TT cells expressing RET{Delta}TK with untreated control cells or control vector-treated cells. Furthermore, 2 weeks after injecting adenovirus-carrying RET{Delta}TK into thyroid glands of transgenic mice with orthotopic medullary thyroid carcinoma, tumors were statistically significantly smaller than their initial size in mice treated with RET{Delta}TK (43.6%, 95% confidence interval [CI] = 30.7% to 56.5%; P = .010; two-sided unpaired Student's t test), whereas tumors in mice treated with a control vector were larger than their initial size (139.8%, 95% CI = 120.3% to 159.3%; P<.001). Conclusion: Selective disruption of oncogenic RET signaling in medullary thyroid carcinoma in vitro and in vivo is associated with loss of the neoplastic phenotype of medullary thyroid carcinoma and should be investigated further as the basis for new therapeutic approaches for this disease.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Cancer Res.Home page
S. Ruiz-Llorente, C. Montero-Conde, R. L. Milne, C. M. Moya, A. Cebrian, R. Leton, A. Cascon, F. Mercadillo, I. Landa, S. Borrego, et al.
Association Study of 69 Genes in the Ret Pathway Identifies Low-penetrance Loci in Sporadic Medullary Thyroid Carcinoma
Cancer Res., October 1, 2007; 67(19): 9561 - 9567.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
N. Akeno-Stuart, M. Croyle, J. A. Knauf, R. Malaguarnera, D. Vitagliano, M. Santoro, C. Stephan, K. Grosios, M. Wartmann, R. Cozens, et al.
The RET Kinase Inhibitor NVP-AST487 Blocks Growth and Calcitonin Gene Expression through Distinct Mechanisms in Medullary Thyroid Cancer Cells
Cancer Res., July 15, 2007; 67(14): 6956 - 6964.
[Abstract] [Full Text] [PDF]

Home page
 Hum Mol GenetHome page
A. Karhu and L. A. Aaltonen
Susceptibility to pituitary neoplasia related to MEN-1, CDKN1B and AIP mutations: an update
Hum. Mol. Genet., April 15, 2007; 16(R1): R73 - R79.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
N. S. Pellegata, L. Quintanilla-Martinez, H. Siggelkow, E. Samson, K. Bink, H. Hofler, F. Fend, J. Graw, and M. J. Atkinson
Germ-line mutations in p27Kip1 cause a multiple endocrine neoplasia syndrome in rats and humans
PNAS, October 17, 2006; 103(42): 15558 - 15563.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.